Home | Welcome to Contract Pharma   
Last Updated Monday, December 22 2014

Print RSS Feed

Financial Report: Gilead Sciences



Published April 23, 2014
Gilead Sciences
 
1Q Revenues: $5.0 billion (+97%)

1Q Earnings: $2.2 billion (+210%)

Comments: Antiviral product sales were up 119% to $4.5 billion, driven by Hepatitis C drug Sovaldi, which launched in December 2013 and had $2.3 billion in sales. Stribild sales were up 134% to $215.3 million and Complera/Eviplera sales were up 69% to $250.7 million.Cardiovascular product sales increased to $234.5 million, up 9% primarily driven by Ranexa sales.


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On